STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses ...

STAAR Surgical（STAA.US ... 公司提供两种类型的产品： 植入式角膜塑形镜（ICL）和人工晶体（IOL）。ICL 用于屈光手术，IOL 用于白内障手术。

根据最新的SEC文件显示，Staar Surgical Co. (NASDAQ:STAA)的主要股东Broadwood Partners, L.P.报告了一系列股票购买交易，总额约为1128万美元。这些交易发生在2025年2月27日至3月3日期间。在过去六个月里，STAA股价下跌了近48%，目前公司市值为8.14亿美元。 此次收购包括多批普通股，购买价格在每股16.00美元至17.99美元之间。通 ...

STAAR Surgical attributed the weak performance to deteriorating demand in China, its largest market. ICL (TASE:ICL) sales in China dropped to just $7.5 million in Q4, dragging down overall ICL ...

Staar Surgical reported a Q4 2024 EPS loss of 69 cents, missing the consensus, with revenue dropping 36% to $48.9 million. The company expects 2025 ICL sales outside China to grow 9%-15% but ...

STAAR Surgical（STAA.US ... 公司提供两种类型的产品： 植入式角膜塑形镜（ICL）和人工晶体（IOL）。ICL 用于屈光手术，IOL 用于白内障手术。

Mizuho has downgraded STAAR Surgical (NASDAQ:STAA ... The investment bank said the "sharpness of the correction" of China ICL sales in Q4 and "very modest" outlook for the first half of 2025 ...

In this Healio Video Perspective from Telling It Like It Is, Matt Hirabayashi, MD, shares pearls on ICL sizing and discusses ...

ICL sales of $312.5 million ... Chair of the Board and CEO of STAAR Surgical. "China is the largest market in the world for refractive procedures, and macroeconomic conditions and consumer ...

LAKE FOREST, Calif., February 11, 2025--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, ...

(RTTNews) - Shares of STAAR Surgical Company (STAA ... family for refractive surgery to treat myopia (nearsightedness). ICL sales were $46.9 million for the fourth quarter of 2024 compared ...